Cobra Biologics has acquired Unitech Pharma Group and its bioproduction facility in Matfors near Sundsvall, Sweden, expanding capacity and biopharmaceutical service offerings. Unitech has a 600L clinical and commercial microbial GMP production capacity, commercial aseptic fill/finish and lyophilization capability. Financial terms were not disclosed.   Peter Coleman, chief executive officer of Cobra, said, “I am delighted to announce this acquisition as it significantly enhances Cobra’s servi...